News
NVAX
4.780
-1.44%
-0.070
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
NASDAQ · 1d ago
Weekly Report: what happened at NVAX last week (0318-0322)?
Weekly Report · 4d ago
US STOCKS-Wall St ends higher as Fed keeps three rate cuts on the horizon
Wall St ends higher as Fed keeps three rate cuts on the horizon. Fed holds rates steady as expected, keeps 3 rate cuts in sight. Stocks gain after statement that raised growth outlook and lowered unemployment rate projection. Nine of the S&P's 11 major sectors advanced.
Reuters · 03/20 20:49
US STOCKS-Wall St advances as US Fed keeps three rate cuts on the horizon
Wall St advances as US Fed keeps three rate cuts on the horizon. Federal Reserve eases jitters by keeping borrowing costs unchanged. Fed chair Jerome Powell says inflation moving down gradually. The S&P 500 and the Dow Jones Industrial Average both rise. Most of the S-P's 11 major sectors gained ground.
Reuters · 03/20 20:00
US STOCKS-Wall St holds ground ahead of Fed decision
Wall Street's main stock indexes were little changed ahead of the conclusion of the Federal Reserve's meeting. The Fed is expected to keep interest rates unchanged. Seven of the 11 major S&P 500 sectors were up. PDD Holdings up after Q4 rev beats estimates, Chipotle Mexican Grill up.
Reuters · 03/20 16:02
BUZZ-BioNTech falls on downbeat 2024 revenue forecast
U.S-listed shares of BioNTech 22UAy.DE, BNTX.O fall 6.7% to $87.8. Germany-based company sees 2024 revenue between 2.5 billion euros and 3.1 billion euros below analysts' estimates.
Reuters · 03/20 15:19
Novavax (NASDAQ:NVAX): A Highly Speculative Value Trade in the Post-Pandemic Era
TipRanks · 03/19 04:19
Weekly Report: what happened at NVAX last week (0311-0315)?
Weekly Report · 03/18 09:07
(NVAX) - Analyzing Novavax's Short Interest
Novavax's short percent of float has risen 5.26% since its last report. The company has 54.83 million shares sold short, which is 55.43% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 03/15 14:45
Novavax, Inc. Says Canada National Advisory Committee Publishes Recommendation For Use Of Novavax's Nuvaxovid XBB.1.5 Covid-19 Vaccine; Recommendations State That Nuvaxovid XBB.1.5 Can Be Used In Unvaccinated Or Previously Vaccinated Individuals Aged 12 Years And Older
Benzinga · 03/11 13:20
Weekly Report: what happened at NVAX last week (0304-0308)?
Weekly Report · 03/11 09:07
India's Serum looks beyond COVID with new vaccines for malaria, dengue
India's Serum looks beyond COVID with vaccines for malaria, dengue. CEO of the world's biggest vaccine maker, Serum Institute of India, says company has bolstered its manufacturing. Serum is repurposing facilities used to make COVID-19 immunizations. The company is also testing vaccines against diseases like malaria and dengued.
Reuters · 03/10 17:30
1 Beaten-Down Stock That's Still Not Worth Buying
Novavax is a biotech stock down 97% over the past three years. The company has no other approved products right now. Novavax has a promising candidate for a combined coronavirus/flu vaccine. But the company's prospects don't look attractive. Investors should stay away from the company.
The Motley Fool · 03/09 06:59
FDA experts recommend changes to flu shots
Healthcare FDA experts recommend changes to flu shots for the 2024–2025 season. Group of independent advisers to the FDA voted unanimously to recommend changing the flu vaccines to reflect only the currently circulating viral strains. The move could potentially boost vaccine supplies. The group recommended against adding the vaccine component that targets the B/Yamagata lineage.
Seeking Alpha · 03/07 18:29
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
Two beaten-down biotech stocks soared in the earlier days of the pandemic. Novavax and Ocugen both developed coronavirus vaccine candidates. One reached commercialization but sales disappointed, while the other hasn't yet reached the vaccine finish line. Wall Street is enthusiastic about these two stocks, but they could be overvalued.
The Motley Fool · 03/07 10:28
Another update to COVID shots expected this year, CDC chief says
Another update to COVID shots expected this year, CDC chief says. Researchers are working on strain selection for the upcoming vaccine version expected to be rolled out this fall. Initial studies are underway to introduce another update to the COVID-19 vaccines in the U.S.
Seeking Alpha · 03/05 13:09
Weekly Report: what happened at NVAX last week (0226-0301)?
Weekly Report · 03/04 09:07
Novavax: Another Day Older And Deeper In
Novavax's prospects for success in 2024 are dim. The company's Q4 2023 earnings were a miss that roiled the market. There can be no assurance that Novavax can continue as a going concern. It has failed to develop a standalone vaccine against the flu.
Seeking Alpha · 03/02 14:30
Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry
Novavax's share price has bounced 35% in the last month but is still down 30% in 12 months. The company's price-to-sales ratio of 0.8x is lower than the industry median. Novavax could be doing better as its revenue has been going backwards. Its forecast growth is also lower than other companies in the same industry.
Simply Wall St · 03/02 13:44
Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00
Novavax, Inc. (NASDAQ:NVAX) released its yearly results last week. Revenues of US$984m missed analyst predictions by 3.0%. The company reported a statutory loss per share of US$5.41. Novavax's revenues are expected to fall to US$777.9m in 2024. The analysts have revised down their revenue estimates for next year. The company is expected to have a lower price target for the year after the report.
Simply Wall St · 03/01 13:15
More
Webull provides a variety of real-time NVAX stock news. You can receive the latest news about Novavax Inc through multiple platforms. This information may help you make smarter investment decisions.
About NVAX
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.